NCT04125719View on ClinicalTrials.gov

PVSRIPO in Combination With Nivolumab in Melanoma

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 1, 2020

Primary Completion Date

October 1, 2024

Study Completion Date

October 1, 2024

Conditions
Melanoma
Interventions
BIOLOGICAL

PVSRIPO

Intralesional injection of PVSRIPO

DRUG

Nivolumab

Nivolumab infusion

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors
All Listed Sponsors
collaborator

Duke University

OTHER

collaborator

Istari Oncology, Inc.

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Darell Bigner

OTHER